review, we cannot guarantee that we will be able to do so.

Abstract: The principal purpose for collecting the requested information is to recruit eligible students to participate in Reclamation's Technical Service Center Summer Intern Program. General contact information will be collected along with information on academic standing and areas/fields of interest. Respondents are also asked to submit an interest letter and resume.

Title of Collection: Technical Service Center Summer Intern Program Application.

ÖMB Control Number: 1006–NEW. Form Number: 7–3000.

Type of Review: New, in use without OMB approval.

Respondents/Affected Public: Students interested in internships at Reclamation.

Total Estimated Number of Annual Respondents: 150.

Total Estimated Number of Annual Responses: 150.

Estimated Completion Time per Response: 140 minutes.

Total Estimated Number of Annual Burden Hours: 350 hours.

Respondent's Obligation: Required to obtain or retain a benefit.

Frequency of Collection: Annually. Total Estimated Annual Non-hour Burden Cost: \$0.

An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.

The authority for this action is the Paperwork Reduction Act of 1995 (44 U.S.C. $3501 \ et\ seq$).

Richard LaFond,

Director, Technical Service Center. [FR Doc. 2022–14047 Filed 6–29–22; 8:45 am] BILLING CODE 4332–90–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-1032]

[DOCKET NO. DEA-1032]

Importer of Controlled Substances Application: Cambrex Charles City

AGENCY: Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: Cambrex Charles City has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and

applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 1, 2022. Such persons may also file a written request for a hearing on the application on or before August 1, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

supplementary information: In accordance with 21 CFR 1301.34(a), this is notice that on May 9, 2022, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616–3466, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Drug code | Schedule |
|--------------|--------------------------------------|
| 7437 | ı |
| 8333 | H |
| | |
| | |
| 8501 | l II |
| 9040 | l II |
| 9600 | l II |
| 9670 | l II |
| | |
| | 7437 8333 8501 9040 9600 |

The company plans to import the listed controlled substances for internal use and to bulk manufacture other controlled substances into active pharmaceutical ingredient (API) form for distribution to its customers. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Kristi O'Malley,

Assistant Administrator.
[FR Doc. 2022–14041 Filed 6–29–22; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-1027]

Importer of Controlled Substances Application: Adiramedica, LLC

AGENCY: Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: Adiramedica, LLC. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 1, 2022. Such persons may also file a written request for a hearing on the application on or before August 1, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal